Xellia Pharmaceuticals successfully finalized a project on developing liquid antibiotics and active substances with antibiotic-like stabilization mechanisms for intravenous and intramuscular application.
Zagreb, Croatia and Copenhagen, Denmark, 29 September 2023 - Xellia Pharmaceuticals (“Xellia”), a global leader in the manufacturing of specialty anti-infective treatments, announces the successful finalization of the project co-financed by the European Union from the European Regional Development Fund. Within this Industrial Research and Innovation (IRI) Grant from the Croatian Ministry of Economy and Sustainable Development and the Agency for SMEs, Innovations, and Investments, Zagreb R&D Center-of-Excellence (Xellia d.o.o, Croatia) was enabled to work on the implementation of the project "Development of liquid antibiotics and active substances with antibiotic-like stabilization mechanisms for intravenous and intramuscular application" in the period from February 17th 2020 to August 17th 2023. During this period, a total contribution of financing from the EU of 3.044.709,48 EUR (22.940.363,56 HRK) was received, where the total project value is estimated at 6.715.941,84 EUR (50.601.263,82 HRK).
This Grant brought Xellia’s innovation and development of value-added anti-infective treatments a step further. With focused R&D capabilities within this area, and through the support of the Grant, substantial progress in the development of liquid formulations was made, working towards Xellia's purpose to save lives through innovating critical care and anti-infective therapies.
During the project, Xellia has developed a unique, innovative platform, for accelerated development of advanced liquid formulations of predefined active substances. The basis of this interdisciplinary and innovative platform is a methodology that enables quick screening of excipients and characterization of their influence on the active substance.
Through disseminating the results (one original scientific paper and two poster presentations), the contribution of the interdisciplinary, innovative approach to the development of formulations was demonstrated, and the developed platform justified its purpose.
In addition, adopted methodology and knowledge have already been implemented in developing new innovative projects, resulting in several patent applications.
*The project is co-financed by the European Union from the European Regional Development Fund.
*The content of the website is the sole responsibility of Xellia Pharmaceuticals.
For more information, please contact:
Snježana Mirić, Senior Director, R&D Zagreb and Deputy Site Leader Zagreb
Tel: +45 32 64 55 00 / +385 1 6610 629
Instinctif Partners (International media relations)
Melanie Toyne-Sewell / Rozi Morris/ Batoul Ali
Tel: +44 (0) 20 7457 2020